$HWKN

HAWKINS INC (HWKN): Results of Operations and Financial Condition

HAWKINS INC (HWKN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hwknex9912027-q1.htm EX-99.1 Document Exhibit 99.1 Hawkins, Inc. Reports First Quarter Fiscal 2027 Results Roseville, Minn., July 29, 2026 – Hawkins, Inc. (Nasdaq: HWKN) today announced results for the three months ended June 28, 2026, its first quarter of fiscal 2027.

Original reporting
Published Jul 29, 2026, 8:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$HWKN
Bullish
medium confidence
Mentioned
$HWKN
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HWKNBullishMed
01

Why it matters

Traders can update near-term expectations for Hawkins’ FY2027 based on record top-line and cash generation, while monitoring margin headwinds tied to LIFO and freight and the effect of the Aqua-Chem acquisition.

02

Market read

Record revenue, adjusted EBITDA, and free cash flow with a small EPS decline, plus explicit margin headwinds and a small acquisition funded by FCF.

03

What to watch

SG&A rose 14% year over year (including non-recurring earnout adjustment not recurring), which could cap operating leverage even with revenue growth.

Relevance 7/10Novelty 7/10Timing: after-hours filing of Q1 FY2027 results on SEC 8-K

Background

SEC 8-K Item 2.02 with Exhibit 99.1 reporting Hawkins’ first quarter of fiscal 2027 results for the three months ended June 28, 2026.

Company-level read

Ticker impact

$HWKNBullishMedium confidence
Context

Hawkins reported Q1 FY2027 results, including record revenue of $315.7M (+8%) and diluted EPS of $1.35, plus $23.5M free cash flow.

Expected impact

Near-term bias positive on growth and cash generation, partially offset by margin headwinds and EPS decline.

Evidence & confidence

The filing provides multiple concrete datapoints (revenue, EPS, FCF, leverage, margin drivers) that can shift expectations for near-term earnings quality and FY2027 trajectory.

Market effects

Read-through for distributors serving water treatment, food and health sciences, and industrial solutions on demand resilience and input-cost volatility management.

Limited; company-specific performance with no stated regional macro catalyst.

Limited; no global macro or international regulatory developments disclosed.

Counterpoint

Gross profit and margin were pressured by LIFO reserve increases and freight costs, so the quality of earnings may be less durable if input costs re-accelerate.

Key entities

  • Hawkins, Inc.

    Nasdaq-listed distributor reporting Q1 FY2027 revenue, EPS, cash flow, and acquisition/buyback/dividend activity.

  • Aqua-Chem, Inc.

    Water treatment product distributor acquired for $3.6 million, mainly in Nebraska and Iowa.

Related articles

$CRWVMed

CoreWeave Stock Buy or Sell Debate Intensifies in 2026 After Q2 Beat and $104 Billion Backlog

CoreWeave Inc. shares closed at $105.26 on Aug. 14, 2026 after its Q2 results. Revenue rose to $2.58B from $1.21B a year earlier; adjusted operating income was $128M, but GAAP net loss widened to $626M due to higher interest expense. The company raised 2026 revenue guidance to $12.4B-$13.2B and projected adjusted operating income of $960M-$1.15B. Backlog was about $104B.

$CELCMed

Celcuity Q2 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.

$CBUSMed

Cibus Q2 Earnings Call Highlights

Cibus (NASDAQ:CBUS) reported cash and cash equivalents of $20.4 million as of June 30. Management said cash burn declined 19% sequentially and 31% year over year, with existing cash expected to fund operations and capex into early Q1 2027. Guidance updates include shifting an initial Latin America rice launch to 2028 and targeting biofragrance revenue of $20 million to $40 million when commercialized.

$ICFIMed

ICF International (ICFI) Q2 2026 Earnings Call Transcript

ICF International (ICFI) reported Q2 2026 results on an earnings call, citing revenue growth from federal and a 35% rise in international government clients. Adjusted EBITDA margin was 11.2% and non-GAAP EPS rose 12%. Book-to-bill was 1.09x, pipeline $9.3B, and contracts awarded over $200M since quarter-end. Share repurchases exceeded 435k shares.

$NOGMedAI 8/10

Northern Oil and Gas (NOG) Q2 2026 Earnings Call Transcript

Northern Oil and Gas (NOG) reported Q2 2026 results in an earnings call. Adjusted EBITDA rose 17% sequentially and free cash flow increased over 400% from Q1. Production was up 9% YoY, with record natural gas volumes up 35% YoY. The company repurchased 2.95M shares at $20.37 and declared a $0.45 dividend.